HK1173949A1 - Glp-2 for use in the treatment of muscle atrophy glp-2 - Google Patents

Glp-2 for use in the treatment of muscle atrophy glp-2

Info

Publication number
HK1173949A1
HK1173949A1 HK13100959.4A HK13100959A HK1173949A1 HK 1173949 A1 HK1173949 A1 HK 1173949A1 HK 13100959 A HK13100959 A HK 13100959A HK 1173949 A1 HK1173949 A1 HK 1173949A1
Authority
HK
Hong Kong
Prior art keywords
glp
treatment
muscle atrophy
atrophy
muscle
Prior art date
Application number
HK13100959.4A
Other languages
English (en)
Chinese (zh)
Inventor
Didier Attaix
Audrey Codran-Raison
Irne Corthesy-Theulaz
Denis Breuille
Lydie Combaret
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of HK1173949A1 publication Critical patent/HK1173949A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK13100959.4A 2009-10-07 2013-01-22 Glp-2 for use in the treatment of muscle atrophy glp-2 HK1173949A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172398A EP2311486A1 (de) 2009-10-07 2009-10-07 GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung
PCT/EP2010/065021 WO2011042501A2 (en) 2009-10-07 2010-10-07 The intestine and muscle recovery

Publications (1)

Publication Number Publication Date
HK1173949A1 true HK1173949A1 (en) 2013-05-31

Family

ID=41611235

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13100959.4A HK1173949A1 (en) 2009-10-07 2013-01-22 Glp-2 for use in the treatment of muscle atrophy glp-2

Country Status (12)

Country Link
US (1) US20120270786A1 (de)
EP (2) EP2311486A1 (de)
JP (1) JP5801814B2 (de)
CN (1) CN102711803B (de)
AU (1) AU2010305420B2 (de)
BR (1) BR112012009380A2 (de)
CA (1) CA2776964C (de)
DK (1) DK2485756T3 (de)
ES (1) ES2539917T3 (de)
HK (1) HK1173949A1 (de)
IN (1) IN2012DN03187A (de)
WO (1) WO2011042501A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909211C (en) * 2013-04-15 2021-06-22 Nestec S.A. Use of whey protein in combination with electrical muscle stimulation
JP6325215B2 (ja) * 2013-08-29 2018-05-16 テルモ株式会社 栄養補給用冷菓
WO2016058919A1 (en) * 2014-10-14 2016-04-21 Nestec S.A. Improvement in muscle functionality of elderly males
US10993993B2 (en) 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
KR101661332B1 (ko) * 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
KR102119188B1 (ko) * 2018-11-13 2020-06-08 이뮤노포지 주식회사 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661123A (en) * 1995-01-17 1997-08-26 Nestec, Ltd. Enteral composition for malabsorbing patients
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) * 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
AU733857B2 (en) * 1996-04-12 2001-05-31 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
CA2223198A1 (en) * 1997-01-14 1998-07-14 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
CA2236519C (en) * 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
EP1090636A1 (de) * 1999-09-13 2001-04-11 Société des Produits Nestlé S.A. Diät mit hohem Lipidgehalt
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002022151A2 (en) * 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
AU2002233089B2 (en) * 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
MXPA05003797A (es) * 2002-10-14 2005-06-08 Novo Nordisk As Variantes de peptido-2 tipo glucagon.
US20040115708A1 (en) * 2002-10-28 2004-06-17 Ardies C. Murray Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia
WO2004103390A2 (en) * 2003-05-15 2004-12-02 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
WO2006108008A2 (en) * 2005-04-06 2006-10-12 Novartis Ag A method and composition for nutritionally improving glucose control and insulin action
EP2340724A3 (de) * 2006-01-09 2012-02-29 Nestec S.A. Behandlung von gestressten Patienten
CN101573376B (zh) * 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2(glp-2)类似物

Also Published As

Publication number Publication date
WO2011042501A3 (en) 2011-06-03
JP5801814B2 (ja) 2015-10-28
DK2485756T3 (en) 2015-06-08
CA2776964A1 (en) 2011-04-14
WO2011042501A2 (en) 2011-04-14
EP2311486A1 (de) 2011-04-20
CA2776964C (en) 2019-03-05
ES2539917T3 (es) 2015-07-07
BR112012009380A2 (pt) 2021-06-22
EP2485756B1 (de) 2015-05-20
CN102711803B (zh) 2017-02-22
JP2013507341A (ja) 2013-03-04
CN102711803A (zh) 2012-10-03
EP2485756A2 (de) 2012-08-15
AU2010305420B2 (en) 2015-03-19
US20120270786A1 (en) 2012-10-25
AU2010305420A1 (en) 2012-05-10
IN2012DN03187A (de) 2015-09-25

Similar Documents

Publication Publication Date Title
EP2435139A4 (de) Zusammensetzungen zur verwendung bei der reduzierung der übertragung menschlicher krankheitserreger
GB0803018D0 (en) Therapeutic compounds and their use
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
GB0804685D0 (en) Therapeutic compounds and their use
IL218212A0 (en) Therapeutic methods and compositions
GB0807609D0 (en) Therapeutic compounds and their use
EP2429584A4 (de) Behandlungsverfahren und -zusammensetzungen
GB0822011D0 (en) Treatment
GB0817207D0 (en) therapeutic apsac compounds and their use
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
HK1173949A1 (en) Glp-2 for use in the treatment of muscle atrophy glp-2
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0811992D0 (en) Treatment
GB0900599D0 (en) Treatment
SI2491005T1 (sl) Uporaba 4-(etil(dimetil)amonio)butanoata pri zdravljenju bolezni srca in oĺ˝ilja
EP2461870A4 (de) Therapeutische zusammensetzungen und verfahren
GB0901465D0 (en) Compounds for use in therapy
GB0812913D0 (en) Therapeutic compounds and their use
PL2263454T3 (pl) Kompozycja uzdatniająca
EP2512504A4 (de) Behandlungszusammensetzung und -verfahren
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
GB0820972D0 (en) Treatment
GB0805912D0 (en) Treatment